Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board Member Appointments build the financial and […]
Miguel Forte, current President of the International Society for Cell & Gene Therapy (ISCT), joins Blue Cell as a Non-Executive Director Highly experienced executive with deep scientific expertise, who has helped lead numerous private and public cell therapy biotechs, establishing corporate structures and raising funds Appointment comes as Blue Cell advances its groundbreaking “off-the-shelf” allogeneic […]
May 15, 2025 – Novo Holdings is pleased to announce the appointments of Jun Sung Kim, Lars Green, N.P. “Narv” Narvekar and Torsten Sløk to its Board of Directors, effective May 14, 2025. These distinguished leaders bring a broad range of investment expertise spanning both U.S. and international markets, further strengthening the Board’s global perspectives […]
Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform. Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms, growing scientific teams and managing partnerships with Pharma companies Appointment comes as Commit looks to progress towards […]
Funds will be used to advance Magenta’s US clinical programs to support the FDA’s approval of the Elevate™ System, the world’s smallest heart pump Eric Snyder, Partner, Venture Investments, Novo Holdings will join Magenta Medical Board of Directors Boston, US, 23 July 2024 – Novo Holdings, a leading life science investor, today announces that it has […]
